The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2024 | Challenges with BTKi cardiotoxicity: what can be done to optimize long-term cardiac outcomes?
BTK inhibitors (BTKis) are highly effective and convenient agents for the treatment of chronic lymphocytic leukemia (CLL), however they can induce cardiotoxicity. Kerry Rogers, MD, Ohio State University, Columbus, OH, discusses the available evidence and limitations of various strategies to manage BTKi-related cardiotoxicity, including the use of newer covalent BTKis like acalabrutinib and zanubrutinib. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
